Heart Failure Certification (HF-C) Practice
Exam Questions and Correct Answers
(Verified Answers) Plus Rationales
Question 1
Who would be the appropriate provider for a post hospital? Follow up appointment
it's like two that apply.
Correct Answer
PCP, cardiology
Question 2
Acute congestive heart failure patients require the car outlined in the CPG's. Which of
these patients would be considered acute.
Correct Answer
New diagnosis
Question 3
Heart rate and blood pressure
Correct Answer
Beta blockers
Question 4
The heart being on a board to pump enough blood into the pulmonary circulation is
indicative of
Correct Answer
Right sided heart failure
Page 1 of 70
,Question 5
Causes of heart failure
Correct Answer
Diabetes, HTN, CAD
Question 1: Which of the following is the primary pathophysiologic
mechanism underlying the progressive ventricular remodeling observed in
chronic heart failure with reduced ejection fraction?
A. Isolated diastolic dysfunction without neurohormonal activation
B. Sustained activation of the renin-angiotensin-aldosterone and sympathetic
nervous systems
C. Primary mitochondrial dysfunction independent of hemodynamic stress
D. Acute coronary plaque rupture leading to irreversible myocyte loss
CORRECT ANSWER: B. Sustained activation of the renin-angiotensin-
aldosterone and sympathetic nervous systems
Rationale: Chronic neurohormonal activation drives myocyte hypertrophy, interstitial
fibrosis, and progressive chamber dilation, which are central to adverse ventricular
remodeling in HFrEF. Blocking these pathways forms the foundation of guideline-
directed medical therapy.
Question 2: According to the ACC/AHA staging system, a patient with
structural heart disease who has never experienced symptoms of heart failure
is classified as which stage?
A. Stage A
B. Stage B
C. Stage C
D. Stage D
CORRECT ANSWER: B. Stage B
Rationale: Stage B denotes structural heart disease without current or prior
symptoms of heart failure. Stage A is high risk without structural disease, Stage C is
structural disease with prior or current symptoms, and Stage D is refractory
advanced heart failure.
Question 3: Which laboratory biomarker is most specific for the diagnosis of
acute decompensated heart failure when measured in a patient presenting
with dyspnea?
A. High-sensitivity troponin I
B. B-type natriuretic peptide (BNP) or NT-proBNP
Page 2 of 70
,C. C-reactive protein
D. Serum creatinine
CORRECT ANSWER: B. B-type natriuretic peptide (BNP) or NT-proBNP
Rationale: BNP and NT-proBNP are released in response to ventricular wall stress
and have high negative predictive value for excluding acute heart failure in dyspneic
patients. Other markers assess ischemia, inflammation, or renal function but lack
comparable diagnostic specificity for heart failure.
Question 4: In patients with heart failure with reduced ejection fraction, which
pharmacologic class has been shown to reduce both morbidity and mortality
through inhibition of neprilysin and angiotensin receptors?
A. ACE inhibitors alone
B. Angiotensin receptor-neprilysin inhibitors (ARNIs)
C. Mineralocorticoid receptor antagonists alone
D. Loop diuretics
CORRECT ANSWER: B. Angiotensin receptor-neprilysin inhibitors (ARNIs)
Rationale: Sacubitril/valsartan simultaneously blocks angiotensin receptors and
inhibits neprilysin, increasing beneficial natriuretic peptides while reducing harmful
angiotensin II effects, resulting in superior outcomes compared with ACE inhibitors
in HFrEF.
Question 5: Which of the following is the preferred initial diuretic class for
volume management in most patients with acute decompensated heart
failure?
A. Thiazide diuretics
B. Loop diuretics
C. Potassium-sparing diuretics
D. Carbonic anhydrase inhibitors
CORRECT ANSWER: B. Loop diuretics
Rationale: Loop diuretics act on the thick ascending limb of the loop of Henle and
produce potent natriuresis and diuresis necessary for rapid relief of congestion in
acute decompensated heart failure. Other classes are less effective as monotherapy
for significant volume overload.
Question 6: A patient with HFrEF, NYHA class II–III symptoms, and LVEF ≤35%
despite optimal medical therapy is most likely to derive mortality benefit from
which device therapy?
A. Permanent pacemaker for sinus node dysfunction
B. Implantable cardioverter-defibrillator (ICD) for primary prevention
Page 3 of 70
, C. Intra-aortic balloon pump
D. Temporary transvenous pacing
CORRECT ANSWER: B. Implantable cardioverter-defibrillator (ICD) for primary
prevention
Rationale: Primary-prevention ICDs reduce sudden cardiac death in selected
patients with HFrEF who remain at elevated risk despite guideline-directed medical
therapy. The other options address different clinical scenarios not primarily
indicated for mortality reduction in stable HFrEF.
Question 7: Which of the following best describes the hemodynamic profile of
a patient with “cold and wet” acute decompensated heart failure?
A. High cardiac output and low systemic vascular resistance
B. Low cardiac output and elevated filling pressures
C. Normal cardiac output and normal filling pressures
D. High cardiac output and elevated filling pressures
CORRECT ANSWER: B. Low cardiac output and elevated filling pressures
Rationale: “Cold and wet” indicates hypoperfusion (low cardiac output) combined
with congestion (elevated filling pressures). This profile often requires inotropic or
vasodilator support in addition to diuresis.
Question 8: In the management of heart failure with preserved ejection
fraction, which therapy has the strongest evidence for reducing heart-failure
hospitalizations?
A. Digoxin
B. SGLT2 inhibitors
C. High-dose loop diuretics as monotherapy
D. Ivabradine
CORRECT ANSWER: B. SGLT2 inhibitors
Rationale: Large randomized trials have demonstrated that SGLT2 inhibitors reduce
the composite of cardiovascular death or heart-failure hospitalization in patients
with HFpEF, independent of diabetes status. Other agents lack comparable outcome
data in this population.
Question 9: Which of the following is an absolute contraindication to the use
of an angiotensin-converting enzyme inhibitor in a patient with heart failure?
A. Mild hyperkalemia (K+ 5.1 mEq/L)
B. Bilateral renal-artery stenosis
C. NYHA class III symptoms
D. Concurrent use of a beta-blocker
Page 4 of 70
Exam Questions and Correct Answers
(Verified Answers) Plus Rationales
Question 1
Who would be the appropriate provider for a post hospital? Follow up appointment
it's like two that apply.
Correct Answer
PCP, cardiology
Question 2
Acute congestive heart failure patients require the car outlined in the CPG's. Which of
these patients would be considered acute.
Correct Answer
New diagnosis
Question 3
Heart rate and blood pressure
Correct Answer
Beta blockers
Question 4
The heart being on a board to pump enough blood into the pulmonary circulation is
indicative of
Correct Answer
Right sided heart failure
Page 1 of 70
,Question 5
Causes of heart failure
Correct Answer
Diabetes, HTN, CAD
Question 1: Which of the following is the primary pathophysiologic
mechanism underlying the progressive ventricular remodeling observed in
chronic heart failure with reduced ejection fraction?
A. Isolated diastolic dysfunction without neurohormonal activation
B. Sustained activation of the renin-angiotensin-aldosterone and sympathetic
nervous systems
C. Primary mitochondrial dysfunction independent of hemodynamic stress
D. Acute coronary plaque rupture leading to irreversible myocyte loss
CORRECT ANSWER: B. Sustained activation of the renin-angiotensin-
aldosterone and sympathetic nervous systems
Rationale: Chronic neurohormonal activation drives myocyte hypertrophy, interstitial
fibrosis, and progressive chamber dilation, which are central to adverse ventricular
remodeling in HFrEF. Blocking these pathways forms the foundation of guideline-
directed medical therapy.
Question 2: According to the ACC/AHA staging system, a patient with
structural heart disease who has never experienced symptoms of heart failure
is classified as which stage?
A. Stage A
B. Stage B
C. Stage C
D. Stage D
CORRECT ANSWER: B. Stage B
Rationale: Stage B denotes structural heart disease without current or prior
symptoms of heart failure. Stage A is high risk without structural disease, Stage C is
structural disease with prior or current symptoms, and Stage D is refractory
advanced heart failure.
Question 3: Which laboratory biomarker is most specific for the diagnosis of
acute decompensated heart failure when measured in a patient presenting
with dyspnea?
A. High-sensitivity troponin I
B. B-type natriuretic peptide (BNP) or NT-proBNP
Page 2 of 70
,C. C-reactive protein
D. Serum creatinine
CORRECT ANSWER: B. B-type natriuretic peptide (BNP) or NT-proBNP
Rationale: BNP and NT-proBNP are released in response to ventricular wall stress
and have high negative predictive value for excluding acute heart failure in dyspneic
patients. Other markers assess ischemia, inflammation, or renal function but lack
comparable diagnostic specificity for heart failure.
Question 4: In patients with heart failure with reduced ejection fraction, which
pharmacologic class has been shown to reduce both morbidity and mortality
through inhibition of neprilysin and angiotensin receptors?
A. ACE inhibitors alone
B. Angiotensin receptor-neprilysin inhibitors (ARNIs)
C. Mineralocorticoid receptor antagonists alone
D. Loop diuretics
CORRECT ANSWER: B. Angiotensin receptor-neprilysin inhibitors (ARNIs)
Rationale: Sacubitril/valsartan simultaneously blocks angiotensin receptors and
inhibits neprilysin, increasing beneficial natriuretic peptides while reducing harmful
angiotensin II effects, resulting in superior outcomes compared with ACE inhibitors
in HFrEF.
Question 5: Which of the following is the preferred initial diuretic class for
volume management in most patients with acute decompensated heart
failure?
A. Thiazide diuretics
B. Loop diuretics
C. Potassium-sparing diuretics
D. Carbonic anhydrase inhibitors
CORRECT ANSWER: B. Loop diuretics
Rationale: Loop diuretics act on the thick ascending limb of the loop of Henle and
produce potent natriuresis and diuresis necessary for rapid relief of congestion in
acute decompensated heart failure. Other classes are less effective as monotherapy
for significant volume overload.
Question 6: A patient with HFrEF, NYHA class II–III symptoms, and LVEF ≤35%
despite optimal medical therapy is most likely to derive mortality benefit from
which device therapy?
A. Permanent pacemaker for sinus node dysfunction
B. Implantable cardioverter-defibrillator (ICD) for primary prevention
Page 3 of 70
, C. Intra-aortic balloon pump
D. Temporary transvenous pacing
CORRECT ANSWER: B. Implantable cardioverter-defibrillator (ICD) for primary
prevention
Rationale: Primary-prevention ICDs reduce sudden cardiac death in selected
patients with HFrEF who remain at elevated risk despite guideline-directed medical
therapy. The other options address different clinical scenarios not primarily
indicated for mortality reduction in stable HFrEF.
Question 7: Which of the following best describes the hemodynamic profile of
a patient with “cold and wet” acute decompensated heart failure?
A. High cardiac output and low systemic vascular resistance
B. Low cardiac output and elevated filling pressures
C. Normal cardiac output and normal filling pressures
D. High cardiac output and elevated filling pressures
CORRECT ANSWER: B. Low cardiac output and elevated filling pressures
Rationale: “Cold and wet” indicates hypoperfusion (low cardiac output) combined
with congestion (elevated filling pressures). This profile often requires inotropic or
vasodilator support in addition to diuresis.
Question 8: In the management of heart failure with preserved ejection
fraction, which therapy has the strongest evidence for reducing heart-failure
hospitalizations?
A. Digoxin
B. SGLT2 inhibitors
C. High-dose loop diuretics as monotherapy
D. Ivabradine
CORRECT ANSWER: B. SGLT2 inhibitors
Rationale: Large randomized trials have demonstrated that SGLT2 inhibitors reduce
the composite of cardiovascular death or heart-failure hospitalization in patients
with HFpEF, independent of diabetes status. Other agents lack comparable outcome
data in this population.
Question 9: Which of the following is an absolute contraindication to the use
of an angiotensin-converting enzyme inhibitor in a patient with heart failure?
A. Mild hyperkalemia (K+ 5.1 mEq/L)
B. Bilateral renal-artery stenosis
C. NYHA class III symptoms
D. Concurrent use of a beta-blocker
Page 4 of 70
